Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.

[1]  Y. Mao,et al.  p53 dependence of topoisomerase I recruitment in vivo. , 2000, Cancer research.

[2]  S. Joel,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1999.6843 , 2022 .

[3]  I. Pollack,et al.  Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. , 1999, Cancer research.

[4]  A. Larsen,et al.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Merlo,et al.  Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.

[6]  R. McLendon,et al.  Topotecan treatment of adults with primary malignant glioma , 1999, Cancer.

[7]  J. Dichgans,et al.  Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses , 1998, International journal of cancer.

[8]  M. Weller,et al.  Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  R. Brown,et al.  Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. , 1998, British Journal of Cancer.

[10]  S. Kaku,et al.  Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. , 1998, Cancer research.

[11]  J. Dichgans,et al.  Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression. , 1998, European journal of pharmacology.

[12]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[13]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[14]  L. Bracco,et al.  Modulation of DNA topoisomerase I activity by p53. , 1996, Biochemistry.

[15]  E. Eisenhauer,et al.  Phase II study of topotecan in patients with recurrent malignant glioma , 1996 .

[16]  E. Kraut,et al.  Analysis of topoisomerase I/DNA complexes in patients administered topotecan. , 1995, Cancer research.